Posted by Michael Wonder on 25 May 2017
Transparency Commission publishes its review of Keytruda's SMR & ASMR
22 May 2017 - The Transparency Commission has reviewed its SMR & ASMR ratings of pembrolizumab for malignant melanoma.
The available data based on an update of the follow-up of the two studies already evaluated by the Commission (KEYNOTE 001 and KEYNOTE 006) are not likely to modify the assessment of improvement of the minor medical rendering service (ASMR IV) Attributed to Keytruda by the Commission in its opinion of 16 March 2016.
